As HD and AD share similar pathologies of protein aggregation and neurodegeneration, and are both diseases exacerbated by dysregulated inflammation, it may be that the laquinimod‐induced reduction in IL‐10 from HD peripheral myeloid cells is beneficial, and may contribute to resolution of the innate immune system cytokine balance. The gene discussed is IL10; the disease is Huntington disease.